Oncology Precision Medicine Market Dynamics: Current Trends, Segment Analysis & Opportunities Through 2035 The Oncology Precision Medicine Market has been the subject of detailed research in a newly released report that presents a neutral and data-driven view of current and historical trends. The report serves as a reference point for businesses, analysts, and stakeholders seeking to understand key developments, market behavior, and regional segmentation within this domain. Included in the study is a summary of relevant market data, product coverage, technological updates, and emerging segment-level activity. The research report also highlights notable strategies being employed by companies operating in this space. Offered in both PDF and spreadsheet formats, the report is tailored for professionals seeking structured and accessible information on the Oncology Precision Medicine industry. The oncology precision medicine market, valued at USD 166 billion in 2025, is project to reach USD 185 billion in 2026 and USD 364 billion by 2035, representing a CAGR of 7.8% during the forecast period 2026 to 2035. The report offers updated metrics and segment-wise insights to help users stay aligned with market direction and interpret available data effectively. Oncology Precision Medicine Market Characterization Market Scope and Market Size: The market is segmented based on Distribution by Historical Trend: Since 2018, Forecast Period: Till 2035, Market Size 2026: USD 185 Billion, Market Size 2035: USD 364 Billion, CAGR (Till 2035): 7.8%, Type of Cancer Targeted, Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer, Others, Route of Administration, Oral, Intravenous, Others, Type of Molecule, Small Molecules, Biologics, Drug Class, Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors, Others, Leading Drug Developers, Merck, Pfizer, AstraZeneca, Johnson $ Johnson Innovative Medicine, Genentech, Key Geographical Regions, North America (, Europe (, Asia (, Middle East and North Africa (, Latin America (, Key Players, AbbVie, Anticancer Bioscience, Astellas Pharma, Astrazeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, Erasca, Genentech, GlaxoSmithKline, Hutchmed, IDEAYA Biosciences, Jiangsu Hengrui Pharmaceuticals, Johnson & Johnson Innovative Medicine, Merck, Novartis, Pfizer, Repare Therapeutics, Roche, Seagen, SpringWorks Therapeutics, Takeda Pharmaceutical, VERAXA Biotech GmbH, VRise Therapeutics, PowerPoint Presentation (Complimentary): Available, Customization Scope: 15% Free Customization, Excel Data Packs (Complimentary), Market Landscape, Partnerships and Collaborations, Clinical Trial Analysis, Case Study: Oncology Precision Medicine Assay Kits, Market Forecast and Opportunity Analysis. This segmentation offers a clear breakdown of industry structure and allows for comparative assessment across products, use cases, and regions. The report also outlines key differences among various market categories while presenting an overview of performance based on volume and value indicators. Reference: https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html

The Expanding Role of Precision Medicine in Cardiac Arrhythmia Therapeutics Market Growth : Cardiac Arrhythmia Therapeutics Market Opportunities Emerging from Healthcare Innovation : https://www.theinsightpartners.com/reports/cardiac-arrhythmia-therapeutics-market

LNP-mRNA Therapy Market to Grow at 6.1% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global LNP-mRNA therapy market was valued at USD 500 million in 2024 and is projected to reach USD 719 million by 2031, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. LNP-mRNA therapy represents a cutting-edge biomedical technology that leverages the unique strengths of lipid nanoparticles (LNPs) and messenger RNA (mRNA) to offer novel treatment avenues for various diseases. Serving as carriers, LNPs effectively shield mRNA from enzymatic degradation in the body and deliver it precisely to target cells. mRNA carries the genetic information necessary for synthesizing specific proteins; once inside cells, it directs the cells to produce these proteins, thereby triggering immune responses or repairing damaged tissues. This therapy demonstrates significant potential in treating cancers, genetic disorders, and infectious diseases. Its highly personalized and rapid-response characteristics have made LNP-mRNA therapy a research focus in the biomedical field. By precisely regulating gene expression, LNP-mRNA therapy provides patients with unprecedented treatment options, ushering in a new era of precision medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5214/lnp-mrna-therapy-market

Top 10 Companies Advancing the CRISPR Gene Editing Therapy Market According to a newly published market research report by 24LifeSciences, global CRISPR gene editing therapy market was valued at USD 435 million in 2024 and is projected to reach USD 620 million by 2031, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period 2025-2031. CRISPR gene editing therapy represents a revolutionary breakthrough in molecular medicine, enabling precise modifications to the human genome with unprecedented accuracy. The technology utilizes the CRISPR-Cas9 system, derived from bacterial immune mechanisms, to target and edit specific DNA sequences. This capability has profound implications for treating genetic diseases, advancing oncology treatments, combating infectious diseases, and pioneering new approaches in regenerative medicine. Its established efficacy in correcting genetic defects continues to underpin its importance in modern precision medicine and therapeutic innovation. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5194/crispr-gene-editing-therapy-market

Precision Medicine Transforming the Skin Cancer Diagnostics and Therapeutics Market According to a newly published market research report by 24LifeSciences, global skin cancer diagnostics and therapeutics market was valued at USD 8.9 billion in 2024 and is projected to reach USD 15.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period 2025–2031. Skin cancer diagnostics and therapeutics encompass the comprehensive suite of tools, technologies, and pharmaceutical agents utilized for the detection and treatment of malignancies arising in the skin, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and the more aggressive melanoma. This field integrates diagnostic methodologies ranging from visual inspection and dermoscopy to advanced biopsy techniques and molecular profiling, alongside therapeutic interventions that span surgical excision, radiation, targeted therapies, and innovative immunotherapies. The critical importance of early and accurate detection, coupled with effective treatment, underpins this market's vital role in global oncology care and its continued expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8994/skin-cancer-diagnostics-and-therapeutics-market

How Precision Medicine Is Reshaping the Meniere’s Disease Treatment Market According to a newly published market research report by 24LifeSciences, global ophthalmoplegia market value is at USD 1,2 billion in 2026 and is projected to reach USD 1.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.5% during the forecast period. Ophthalmoplegia refers to the paralysis or weakness of one or more of the extraocular muscles responsible for controlling eye movements and pupil function. This condition is not a disease itself but a clinical manifestation of various underlying neurological, muscular, or systemic disorders, including thyroid eye disease, mitochondrial disorders, strokes, tumors, and multiple sclerosis. Its management requires specialized diagnostic evaluation and tailored treatment approaches focused on addressing root causes, ranging from medical therapies to surgical interventions for functional restoration. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9562/ophthalmoplegia-market

Mendelian Disorders Testing Market Size to Reach USD 7.8 Billion by 2032 | Growth Trends & Insights Global Mendelian disorders testing market is gaining strong momentum as healthcare systems worldwide intensify their focus on early diagnosis, preventive screening, and precision medicine. The market is projected to expand from USD 4.6 billion in 2025 to USD 7.8 billion by 2032, registering a robust compound annual growth rate (CAGR) of 7.8% during the forecast period. This sustained growth reflects rising awareness of inherited diseases, expanding newborn and prenatal screening programs, and rapid advancements in genomic testing technologies. Access the market report https://www.24lifesciences.com/mendelian-disorders-testing-market-9526

Immunotherapy Drugs Market Size to Reach USD 464.33 Billion by 2031 | Growth Outlook Global Immunotherapy Drugs market is experiencing a transformative expansion as advances in precision medicine, immune-oncology, and biologic drug development redefine modern disease treatment. Valued at USD 220.86 billion in 2024, the market is projected to reach USD 464.33 billion by 2031, growing at a strong CAGR of 11.5% during the forecast period. This growth reflects the increasing clinical reliance on immune-based therapies across cancer, autoimmune, and inflammatory diseases, supported by sustained innovation and expanding global access. Access the complete report https://www.24lifesciences.com/immunotherapy-drugs-market-8811

Transthyretin Amyloidosis Treatment Market Size to Reach USD 3.2 Billion by 2032 Global Transthyretin Amyloidosis (ATTR) treatment market is undergoing a rapid transformation as breakthroughs in gene-silencing therapies, improved diagnostics, and expanded access to specialty care reshape outcomes for patients with this rare and life-threatening disease. Valued at approximately USD 1.5 billion in 2024, the market is forecast to reach USD 3.2 billion by 2032, expanding at a robust CAGR of over 10%. This sustained growth reflects rising disease recognition, accelerated therapeutic innovation, and increasing investment in orphan and precision medicines worldwide. Access the complete report https://www.24lifesciences.com/transthyretin-amyloidosis-treatment-market-9759